Merck KGaA pharma chief says looking at mid-size deals - paper
German chemicals and drugs company Merck KGaA is in the market for mid-size acquisitions to bolster its pharmaceuticals division, the head of that unit told Swiss business paper Finanz und Wirtschaft.
Trending on the Topix Network
Fri Jul 11, 2014
DEALTALK-Private equity takes on Big Pharma's carve-out challenge
Big Pharma companies are trying to offload low-growth, mature drug portfolios to firms such as Blackstone Group LP and TPG Capital LP which need to figure out how to carve them out, in one of private equity's greatest dealmaking challenges.
Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners
July 11, 2014 The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall.
Thu Jul 10, 2014
Medivation Announces Change in Executive Management Team
Ms. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co.
Jounce Therapeutics Snags Ex-Merck & Co., Inc. Exec For CEO Post
Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer Strong Leadership Team in Place to Advance Novel Immunotherapy Programs Cambridge, Mass.
Wed Jul 09, 2014
Credit Suisse names vice chairman of healthcare group -memo
Credit Suisse AG has named senior banker Tom Davidson vice chairman of its global healthcare group, according to a memo released to employees on Wednesday.
Tue Jul 08, 2014
Merck & Co. PT Raised to $60.00
Leerink Swann's target price suggests a potential upside of 3.15% from the company's current price.
Mon Jul 07, 2014
Belgium's Omega Pharma Said to Explore Sale After Merck OTC Deal
Omega Pharma NV, the Belgian over-the-counter health-care company, is exploring a sale of the business almost three years after it was taken private by its founder, people familiar with the matter said.
Merck & Co., Inc. Uses Legal Threats To Silence Negative Advice About Zetia And Vytorin In Italy
In response to repeated legal threats, a public health doctor in Italy has withdrawn advice to curtail use of a controversial drug.
Merck & Co., Inc.'s Januvia Linked To Increase In Heart Failure Hospitalizations
The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now.
Thu Jul 03, 2014
Cramer's Mad Money - 5 Stocks That Pushed The Dow Higher
The Dow Jones inched toward the 17,000 milestone, and Cramer thinks the bull market can keep running.
Wed Jul 02, 2014
Caterpillar Stock Rating Reaffirmed by Wed
's stock had its "average" rating restated by analysts at Wed in a research report issued to clients and investors on Wednesday.
The 5 best stocks since Dow 16,000
Sometimes you need to sit back and understand why a stock that has been terrific can go higher still and how there may be more points to be had if you are just willing to understand the bull case that brought the stock to an exalted level in the first place.
No Perfect Prescription: Barclays Cuts Bristol-Myers, Upgrades AbbVie
Pharmaceutical stocks like Eli Lilly , Merck and AbbVie had a great first half of 2014.
Merck: Buy The Dip... But Not Yet
We are in the midst of our DIY Dividend Investors Club series which is dedicated to the open discussion and analysis of building and managing a long-term dividend portfolio.
Santen Announces Closing of Asset Purchase Agreement With Respect to...
Santen Pharmaceutical Co., Ltd. announced the closing of an asset purchase agreement which was entered on May 13, 2014 between Merck & Co., Inc. with respect to the acquisition of certain ophthalmology assets, following the fulfillment of all of the transfer conditions, except in some territories, in accordance with the terms of the Agreement.
Tue Jul 01, 2014
Trevena Appoints Julie H. McHugh and Barbara Yanni to the Board of Directors
Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor biased ligands, today announced that Julie H. McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., have joined ... (more)
Telerx Completes Acquisition of C3i to Enhance Pharmaceutical...
Telerx , a leader in U.S. customer care services, today announced that it has completed its acquisition of C3i, a leading provider of technology support services for the life sciences industry.
Isis - Addressing Some Of The Bull Arguments To My Short Thesis
After reading the comments on my initial article on Isis , I thought it might be interesting to try to address some of the intelligent issues raised by readers.
Bayer broadens healthcare line by keeping Merck's consumer brands
German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone brands it bagged as part of a $14 billion buy from U.S. Merck, despite overtures from companies keen to grab them, widening its healthcare line to include consumer goods.